Mars Bioimaging Ltd (MBI) was formed in 2007 to commercialise the ground-breaking the MARS imaging system for its applications in medical diagnosis. The MARS imaging system is based on the new generation Medipix chip licensed out of CERN, Switzerland and technology developed by the University of Canterbury (UC) and partners. It has established itself as the world’s leading spectral (multi-energy ‘true colour’) imaging technology. It is the first commercially available spectral, high definition computed tomography (CT) system and has already demonstrated exciting applications.
Location: New Zealand
Total raised: $15M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.01.2026 | Series A | $15M | Pacific Ch... |
Mentions in press and media 3
| Date | Title | Description |
| 14.01.2026 | MARS Bioimaging Secures $15M to Scale World’s First Portable Spectral CT Scanners | MARS Bioimaging’s Group CEO Dr Ojas Mahapatra (left) with Chairman Chris Stoelhorst What You Should Know – MARS Bioimaging, a New Zealand–headquartered pioneer in medical imaging, secures $15M in Series A funding round. Led by Pacific Chann... |
| 14.09.2024 | Современные детекторы рентгеновского излучения | Введение Рентгеновский снимок руки Альберта фон Кёлликера, сделанный Вильгельмом Рентгеном 23 января 1896 года. Источник Вильгельм Рентген открыл рентгеновское излучение 8 ноября 1895 года, когда проводил эксперименты с катодными лучами в в... |
| - | Mars Bioimaging | “MARS Bioimaging” |